Positron emission tomography in schizophrenia: A new perspective

Journal of Nuclear Medicine

Volumn 51, Issue 4, 2010, Pages 511-520

  Patel, Neva H ^a   Vyas, Nora S ^b,c   Puri, Basant K ^c,d   Nijran, Kuldip S ^a   Al Nahhas, Adil ^a  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LIMERICK   (Ireland)

Author keywords

Cognition; COMT; Dopamine; Genes; Positron emission tomography; Prefrontal cortex; Schizophrenia

Indexed keywords

3 METHYLSPIPERONE C 11; 6 FLUORODOPA F 18; ALTANSERIN F 18; AMISULPRIDE; AMPHETAMINE DERIVATIVE; CARBON 11; CHLORPROMAZINE; CLOZAPINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; FALLYPRIDE C 11; FALLYPRIDE F 18; FLUORINE 18; ISOREMOXIPRIDE; NEUROLEPTIC AGENT; QUETIAPINE; RACLOPRIDE C 11; SEROTONIN 2A RECEPTOR; SETOPERONE F 18; TRACER; UNCLASSIFIED DRUG; VOLINANSERIN C 11; WATER O 15; ZIPRASIDONE;

ARTICLE; BRAIN DISEASE; BRAIN REGION; CINGULATE GYRUS; COGNITIVE DEFECT; COMPARTMENT MODEL; CORPUS STRIATUM; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE COURSE; DOPAMINE RELEASE; DOSE RESPONSE; DRUG BINDING; DRUG MECHANISM; DRUG MEGADOSE; GENETIC PREDISPOSITION; HIPPOCAMPUS; HUMAN; NERVE CELL DIFFERENTIATION; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN BINDING; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; ANIMAL; BRAIN; COMPUTER ASSISTED TOMOGRAPHY; METABOLISM; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; RADIOGRAPHY; REVIEW; SCINTISCANNING;

ANIMALS; BRAIN; HUMANS; POSITRON-EMISSION TOMOGRAPHY; SCHIZOPHRENIA; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77950920160     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.066076     Document Type: Article

References (133)

1. Baxter LR. PET studies of cerebral function in major depression and obsessive-compulsive disorder: the emerging prefrontal cortex consensus. Ann Clin Psychiatry. 1991;3:103-109.
2. Krause J. SPECT and PET of the dopamine transporter in attention-deficit/hyperactivity disorder. Expert Rev Neurother. 2008;8:611-625.
3. 2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA. 2000;97:8104-8109.
4. Gjedde A. Receptor mapping in living human beings by means of positron emission tomography [in Danish]. Ugeskr Laeger. 2001;163:5199-5205.
5. Reith J, Benkelfat C, Sherwin A, et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci USA. 1994;91:11651-11654.
6. Hietala J, Syvälahti E, Vuorio K, et al. Presynaptic dopamine function in striatum of neuroleptic-naïve schizophrenic patients. Lancet. 1995;346:1130-1131.
7. 11C) DOPA and PET. Biol Psychiatry. 1999;46:681-688.
8. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry. 2003;160:13-23.
9. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2:e141.
10. Freedman R. Schizophrenia. N Engl J Med. 2003;349:1738-1749.
11. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med. 1998;4:1241-1243.
12. World Health Organization. World Health Report 2001: Mental Health - New Understanding, New Hope. Geneva, Switzerland:World Health Organization; 2001.
13. Vyas NS, Hadjulis M, Vourdas A, et al. The Maudsley Early Onset Schizophrenia Study: predictors of psychosocial outcome at 4-year follow-up. Eur Child Adolesc Psychiatry. 2007;16:465-470.
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. 4th ed., text revision. Washington, DC: American Psychiatric Association; 2000:297-343.
15. Bilder RM, Bogerts B, Ashtari M, et al. Anterior hippocampal volume reductions predict frontal lobe dysfunction in first episode schizophrenia. Schizophr Res. 1995;17:47-58.
16. Saykin J, Gur RC, Gur RE, et al. Neuropsychological function in schizophrenia: selective impairment in memory and learning. Arch Gen Psychiatry. 1991;48:618-624.
17. Saykin AJ, Shtasel DL, Gur RE, et al. Neuropsychological deficits in neuroleptic naïve patients with first-episode schizophrenia. Arch Gen Psychiatry. 1994;51:124-131. (Pubitemid 24985902)
18. Bilder RM, Goldman RS, Robinson D, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry. 2000;157:549-559.
19. Addington J, Addington D. Neurocognitive and social functioning in schizophrenia: a 2.5 year follow-up study. Schizophr Res. 2000;44:47-56.
20. Hughes C, Kumari V, Soni W, et al. Longitudinal study of symptoms and cognitive function in chronic schizophrenia. Schizophr Res. 2003;59:137-146.
21. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321-330.
22. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull. 2000;26:119-136.
23. Kurtz MM. Neurocognitive impairment across the lifespan in schizophrenia: an update. Schizophr Res. 2005;74:15-26.
24. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 1987;44:660-669. (Pubitemid 17099795)
25. McGlashan TH, Hoffman RE. Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch Gen Psychiatry. 2000;57:637-648.
26. Rapoport JL, Addington AM, Frangou S. The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry. 2005;10:434-449.
27. Cardno AG, Marshall EJ, Coid B, et al. Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. Arch Gen Psychiatry. 1999;56:162-168.
28. Cardno AG, Gottesman II. Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics. Am J Med Genet. 2000;97:12-17.
29. Murray RM, McGuffin P. The New Genetics of Mental Illness. Oxford, England: Butterworth Heinemann; 1991.
30. Blackwood DH, Fordyce A, Walker MT, St Clair DM, Porteous DJ, Muir WJ. Schizophrenia and affective disorders-cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. Am J Hum Genet. 2001;69:428-433.
31. Ekelund J, Hovatta I, Parker A, et al. Chromosome 1 loci in Finnish schizophrenia families. Hum Mol Genet. 2001;10:1611-1617. (Pubitemid 32734313)
32. Stefansson H, Sigurdsson E, Steinthorsdottir V, et al. Neuregulin-1 and susceptibility to schizophrenia. Am J Hum Genet. 2002;71:877-892.
33. Li T, Stefansson H, Gudfinnsson E, et al. Identification of a novel neuregulin-1 at-risk haplotype in Han schizophrenia Chinese patients, but no association with the Icelandic/Scottish risk haplotype. Mol Psychiatry. 2004;9:698-704. (Pubitemid 38932174)
34. Schwab SG, Knapp M, Mondabon S, et al. Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. Am J Hum Genet. 2003;72:185-190.
35. Van den Bogaert A, Schumacher J, Schulze TG, et al. The DTNBP1 (dysbindin) gene contributes to schizophrenia, depending on family history of the disease. Am J Hum Genet. 2003;73:1438-1443.
36. Owen MJ, Williams NM, O'Donovan MC. The molecular genetics of schizophrenia: new findings promise new insights. Mol Psychiatry. 2004;9:14-27.
37. Mattay VS, Goldberg TE, Fera F, et al. Catechol O-methyltransferase val158met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci USA. 2003;100:6186-6191.
38. Shifman S, Bronstein M, SternfeldM, et al. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet. 2002;71:1296-1302.
39. Egan MF, Goldberg TE, Kolachana BS, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA. 2001;98:6917-6922.
40. Malhotra AK, Bates JA, Jaeger J, et al. No evidence for phenotypic variation between probands in case-control versus family-based association studies of schizophrenia. Am J Med Genet. 2002;114:509-511.
41. Goldberg TE, Egan MF, Gscheidle T, et al. Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry. 2003;60:889-896.
42. Ehlis AC, Herrmann MJ, Plichta MM, Fallgatter AJ. Cortical activation during two verbal fluency tasks in schizophrenic patients and healthy controls as assessed by multi-channel near-infrared spectroscopy. Psychiatry Res. 2007;156:1-13.
43. Woodward ND, Jayathilake K, Meltzer HY. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr Res. 2007;90:86-96.
44. International Schizophrenia Consortium. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature. 2008;455:237-241.
45. Walsh T, McClellan JM, McCarthy SE, et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science. 2008;320:539-543.
46. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991;148:1474-1486.
47. Volkow ND, Fowler JS, Gatley SJ, et al. PET evaluation of the dopamine system of the human brain. J Nucl Med. 1996;37:1242-1256. (Pubitemid 26329540)
48. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III - the final common pathway. Schizophr Bull. 2009;35:549-562.
49. Abi-Dargham A, Mawlawi O, Lombardo I, et al. Prefrontal dopamine D1 receptor and working memory in schizophrenia. J Neurosci. 2002;22:3708-3719. (Pubitemid 37465776)
50. 2 receptors in schizophrenia. Biol Psychiatry. 2006;59:919-928.
51. 1 receptors in schizophrenia revealed by PET. Nature. 1997;385:634-636.
52. 1 dopamine receptor binding in neuroleptic-naïve patients with schizophrenia. Am J Psychiatry. 2002;159:761-767.
53. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse. 1987;1:133-152.
54. Kile SJ. Neuropsychiatric update: neuroimaging schizophrenia. Psychopharmacol Bull. 2007;40:156-167.
55. 2 receptor. Rinsho Shinkeigaku. 2007;47:826-828.
56. Kapur S, Mizrahi R, Li M. From dopamine to salience to psychosis-linking biology, pharmacology and phenomenology of psychosis. Schizophr Res. 2005;79:59-68.
57. Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Rev. 1998;28:309-369.
58. Milstein DM, Dorris MC. The influence of expected value on saccadic preparation. J Neurosci. 2007;27:4810-4818.
59. Maher BA. A tentative theory of schizophrenic utterance. Prog Exp Pers Res. 1983;12:1-52.
60. Laruelle M. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry. 1999;46:56-72.
61. Brozoski TJ, Brown RM, Rosvold HE, Goldman PS. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex in rhesus monkey. Science. 1979;205:929-932.
62. Arnsten AF. Catecholamine regulation of the prefrontal cortex. J Psychopharmacol. 1997;11:151-162.
63. Granon S, Passetti F, Thomas KL, Dalley JW, Everitt BJ, Robbins TW. Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex. J Neurosci. 2000;20:1208-1215. (Pubitemid 30220477)
64. Kimberg DY, D'Esposito M, Farah MJ. Effects of bromocriptine on human subjects depends on working memory capacity. Neuroreport. 1997;8:3581-3585. (Pubitemid 27497487)
65. Tunbridge EM, Harrison PJ, Weinberger DR. Catechol-O-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry. 2006;60:141-151.
66. Mehta MA, Owen AM, Sahakian BJ, Mavaddat N, Pickard JD, Robbins TW. Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J Neurosci. 2000;20:RC65 (1-6).
67. Phillips AG, Ahn S, Floresco SB. Magnitude of dopamine release in medial prefrontal cortex predicts accuracy of memory on a delayed response task. J Neurosci. 2004;24:547-553.
68. 18F]fluorodopa study. Arch Gen Psychiatry. 2004;61:134-142.
69. Meyer-Lindenberg A, Miletich RS, Kohn PD, et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci. 2002;5:267-271.
70. Breier A, Su T-P, Saunders R, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA. 1997;94:2569-2574.
71. Laruelle M, Abi-Dargham A, van Dyck CH, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA. 1996;93:9235-9240. (Pubitemid 126585329)
72. 2 densities and the schizophrenic brain. Schizophr Res. 1998;32:201-206.
73. Woolley DW, Shaw E. A biochemical and pharmacological suggestion about certain mental disorders. Proc Natl Acad Sci USA. 1954;40:228-231.
74. 2A receptor and the pathology of schizophrenia: a likely accomplice. J Neurochem. 2003;85:1-13.
75. 2a receptor in schizophrenia. Schizophr Res. 2008;104:185-197.
76. Alfimova MV, Lezheiko TV, Golimbet VE, et al. Investigation of association of the brain-derived neurotrophic factor (BDNF) and a serotonin receptor 2A (5-HTR2A) genes with voluntary and involuntary attention in schizophrenia [in Russian]. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108:62-69.
77. 18F-labeled setoperone. J Neurochem. 1990;54:1744-1754.
78. Biver F, Goldman S, Luxen A, et al. Multicompartmental study of fluorine-18 altanserin binding to brain 5HT2 receptors in humans using positron emission tomography. Eur J Nucl Med. 1994;21:937-946. (Pubitemid 24276573)
79. Ito H, Nyberg S, Halldin C, Lundkvist C, Farde L. PET imaging of central 5-HT2A receptors with carbon-11-MDL 100,907. J Nucl Med. 1998;39:208-214.
80. Trichard C, Paillere-Martinot ML, Attar-Levy D, Blin J, Feline A, Martinot JL. No serotonin 5-HT2A receptor density abnormality in the cortex of schizophrenic patients studied with PET. Schizophr Res. 1998;31:13-17.
81. 18F]setoperone in neuroleptic-naïve patients and normal subjects. Am J Psychiatry. 1999;156:72-78.
82. 2A receptor changes in schizophrenia. Psychiatry Res. 2000;99:123-135.
83. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276. (Pubitemid 18039085)
84. 18F]setoperone. Am J Psychiatry. 2000;157:1016-1018.
85. Trichard C, Paillere-Martinot ML, Attar-Levy D, Recassens C, Monnet F, Martinot JL. Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am J Psychiatry. 1998;155:505-508. (Pubitemid 28207446)
86. 2A receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur Neuropsychopharmacol. 2001;11:105-110.
87. 2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry. 2004;161:818-825.
88. 11C]WAY 100635. Psychopharmacology (Berl). 2006;189:155-164.
89. 11C]DASB. Biol Psychiatry. 2005;57:1510-1516.
90. Hall H, Sedvall G, Magnusson O, Kopp J, Halldin C, Farde L. Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology. 1994;11:245-256. (Pubitemid 24372813)
91. Yang YK, Yu L, Yeh TL, Chiu NT, Chen PS, Lee IH. Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naïve patients with schizophrenia: a dual-isotope SPECT study. Am J Psychiatry. 2004;161:1496-1498.
92. 2 receptors. Life Sci. 1996;59:669-678.
93. Verhoeff NP. Radiotracer imaging of dopaminergic transmission in neuropsychiatric disorders. Psychopharmacology (Berl). 1999;147:217-249.
94. Buchsbaum MS, Christian BT, Lehrer DS, et al. D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr Res. 2006;85:232-244.
95. Bradley GM, Couchman GM, Perlesz A, Nguyen AT, Singh B, Riess C. Multiple-family group treatment for English- and Vietnamese-speaking families living with schizophrenia. Psychiatr Serv. 2006;57:521-530.
96. 18F] fluoro-dopa, an analogue of dopa, and its use in direct external measurements of storage, degradation, and turnover of intracerebral dopamine. Proc Natl Acad Sci USA. 1978;75:464-467.
97. Garnett S, Firnau G, Nahmias C, Chirakal R. Striatal dopamine metabolism in living monkeys examined by positron emission tomography. Brain Res. 1983;280:169-171.
98. 18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate. J Neurochem. 1987;48:1077-1082.
99. 18F-DOPA PET study in patients with schizophrenia: positron emission tomography. Psychiatry Res. 2000;100:1-11.
100. 11C]L-deprenyl-D2) binding in the human brain. Nucl Med Biol. 2000;27:43-49.
101. 18F-fallypride in normal volunteers: blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. Synapse. 2002;46:170-188.
102. Woods RP, Cherry SR, Maziotta JC. Rapid automated algorithm for aligning and reslicing PET images. J Comput Assist Tomogr. 1992;16:620-633.
103. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834-840. (Pubitemid 26292051)
104. Ichise M, Ballinger JR, Tanaka F, et al. Age-related changes in D2 receptor binding with iodine-123-iodobenzofuran SPECT. J Nucl Med. 1998;39:1511-1518. (Pubitemid 28459877)
105. Volkow ND, Wang GJ, Fowler JS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry. 1998;155:1325-1331.
106. Semsei I. On the nature of aging. Mech Ageing Dev. 2000;117:93-108.
107. Andreasen NC, O'Leary DS, Cizadlo T, et al. Schizophrenia and cognitive dysmetria: a positron-emission tomography study of dysfunctional prefrontalthalamic-cerebellar circuitry. Proc Natl Acad Sci USA. 1996;93:9985-9990.
108. 18F]fluoro-L-DOPA PET dynamic data in brain tissue without an irreversible compartment: comparative study of the Patlak and Logan analyses. Radiat Med. 2003;21:47-54.
109. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740-747.
110. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3:1-7.
111. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data: generalizations. J Cereb Blood Flow Metab. 1985;5:584-590.
112. Cumming P, Gjedde A. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms. Synapse. 1998;29:37-61. (Pubitemid 28155704)
113. Howes OD, Montgomery AJ, Asselin MC, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry. 2009;66:13-20.
114. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998;12:426-445.
115. Frith C. Positron emission tomography studies of frontal lobe function: relevance to psychiatric disease. Ciba Found Symp. 1991;163:181-191.
116. Crespo-Facorro B, Paradiso S, Andreasen NC, et al. Recalling word list reveals cognitive dysmetria in schizophrenia patients: a PET study. Am J Psychiatry. 1999;156:386-392.
117. Paradiso S, Andreasen NC, Crespo-Facorro B, et al. Emotions in unmedicated patients with schizophrenia during evaluation with positron emission tomography. Am J Psychiatry. 2003;160:1775-1783.
118. Weinberger DR, Berman KF, Zee RF. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia: I. Regional cerebral blood blow (rCBF) evidences. Arch Gen Psychiatry. 1986;43:114-125.
119. Weinberger DR, Berman KF, Illowsky B. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia: III. A new cohort and evidence for a monoaminergic mechanism. Arch Gen Psychiatry. 1988;45:609-615.
120. Andreasen NC, Rezai K, Alliger R, et al. Hypofrontality in neuroleptic-naïve patients and in patients with chronic schizophrenia: assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry. 1992;49:943-958.
121. Liddle PF, Friston KJ, Frith CD, Hirsch SR, Jones T, Frackowiak ASJ. Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry. 1992;160:179-186.
122. Liddle PF, Lane CJ, Ngan ET. Immediate effects of risperidone on corticostraito-thalamic loops and the hippocampus. Br J Psychiatry. 2000;177:402-407.
123. Fletcher JM, Bohan TP, Brandt ME, et al. Cerebral white matter and cognition in hydrocephalic children. Arch Neurol. 1992;49:818-824.
124. Carter CS, Perlstein W, Ganguli R, Brar J, Mintun M, Cohen JD. Functional hypofrontality and working memory dysfunction in schizophrenia. Am J Psychiatry. 1998;155:1285-1287. (Pubitemid 28402528)
125. Perlstein WM, Carter CS, Noll DC, Cohen JD. Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia. Am J Psychiatry. 2001;158:1105-1113.
126. MacDonald AW, III, Cohen JD, Stenger VA, Carter CS. Dissociating the role of the dorsolateral prefrontal and anterior cingulate cortex in cognitive control. Science. 2000;288:1835-1838.
127. Daniel DG, Weinberger DR, Jones DW, et al. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neurosci. 1991;11:1907-1917.
128. Fu CH, McGuire PK. Functional neuroimaging in psychiatry. Philos Trans R Soc Lond B Biol Sci. 1999;354:1359-1370.
129. Buchsbaum MS, Cappelletti J, Ball R, et al. Positron emission tomographic image measurement in schizophrenia and affective disorders. Ann Neurol. 1984;suppl 15:S157-S165.
130. Farkas T, Wolf AP, Jaeger J, Brodie JD, Christman DR, Fowler JS. Regional brain glucose metabolism in chronic schizophrenia: a positron emission transaxial tomographic study. Arch Gen Psychiatry. 1984;41:293-300. (Pubitemid 14168083)
131. Heckers S, Rauch S, Goff D, et al. Impaired recruitment of the hippocampus during conscious recollection in schizophrenia. Nat Neurosci. 1998;1:318-323. (Pubitemid 128652679)
132. Christian BT, Lehrer DS, Shi B, et al. Measuring dopamine neuromodulation in the thalamus: using [F-18]fallypride PET to study dopamine release during a spatial attention task. Neuroimage. 2006;31:139-152.
133. Vyas NS, Patel NH, Nijran KS, Al-Nahhas A, Puri BK. Can PET/CT imaging advance our understanding of the neurobiology of schizophrenia? Nucl Med Comm. 2010;31:91-93.